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EVALUATING PHARMACOKINETICS AND PHARMACODYNAMICS OF IN-
TRAVENOUS BUSULFAN IN PEDIATRIC PATIENTS RECEIVING BONE
MARROW TRANSPLANTATION
Kim, A.1, Tse, J.1, Moore, T.B.2. 1David Geffen School of Medicine at
UCLA, Los Angeles, CA; 2David Geffen School of Medicine at UCLA,
Los Angeles, CA.
Background: Busulfan (BU) is a commonly used conditioning
agent in bone marrow transplant (BMT). However, it is a narrow
therapeutic index drug which has a strong correlation between
area-under-curve (AUC) and both efficacy and toxicity. Studies in
pediatric patients have suggested that children less than 4 years of
age have a greater clearance and thus lower AUC at standard adult
doses. The goal of this retrospective analysis was to evaluate any
age-related pharmacokinetic and pharmacodynamic differences in
pediatric patients who received BU as a conditioning agent.
Methods: From 2001 to 2006, 21/77 pediatric patients who re-
ceived BMT were reviewed. There were 15 males and 6 females
with a mean age of 6 years. Diagnoses of leukemia (n 5 11), HL
(n5 3), MDS (n5 2), and other (n5 5) were included. 16 patients
received BU 1 cyclophosphamide (CY) while 5 patients received
BU 1 another agent. There were 20 allogeneic and 1 autologous
transplants among which 16 were HLA matched and 5 were mis-
matched. Results: Average BU clearance in patients younger than
4 years old (n 5 8) was 4.1 6 1.0 (ml/min)/kg vs. 3.1 6 0.7 (ml/
min)/kg in patients older than 4 years old (n 5 13) (p 5 0.02).
The corresponding averages for AUC were 998 6 226 mMmin
vs.1155 6 183 mMmin (p 5 0.12). No patients younger than 4
years old developed veno-occlusive disease (VOD) while 5 of the
older patients did (p5 0.044). There were no significant differences
in terms of engraftment, graft-vs-host and relapse. Conclusion:
There were significant age-related pharmacokinetic differences in
pediatric patients less than 4 years of age receiving BU for condi-
tioning prior to BMT. There was a decrease in drug toxicity seen
in these patients. Patients younger than 4 years old might not
need routine pharmacokinetic monitoring.234
CEREBRAL TOXOPLASMOSIS FOLLOWING ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT) FOR MALIGNANT LYM-
PHOMA: MISINTERPRETATION AS RELAPSED LYMPHOMA ON INITIAL
MRI STUDIES
Froehlich, B., Florax, A., Juergens, H., Groll, A.H., Ehlert, K. Children’s
University Hospital, Muenster, Germany.
Introduction: Infections are a major cause of death in allogeneic
hematopoietic stem cell transplant recipients. Cerebral toxoplas-
mosis is a life-threatening, but fortunately rare protozoal infection
even in this high risk population. Establishment of the correct diag-
nosis may be hindered by non-specific clinical symptoms and un-
characteristic findings in imaging studies. Here, we report the
case of a 15-year-old boy with disseminated anaplastic large cell
lymphoma (ALCL) and post –transplant cerebral toxoplasmosis
misinterpreted as relapsed lymphoma on initial MRI.Case Report:
The 15-year old boy received an allogeneic HSCT from a matched
unrelated donor for treatment of refractory ALCL. Central nervous
system involvement was excluded by normal MRI studies and the
absence of lymphoma cells in cerebrospinal fluid (CSF). Complica-
tions until day1100 included acute GvHD, grade II, viral reactiva-
tions (polyomavirus, CMV and EBV) and a delayed immune system
recovery. Four months post-transplant, he presented with severe
headaches, fever and nausea. A cranial CT scan revealed multiple
hypodense areas in both hemispheres without hemorrhage or evi-
dence of elevated intracranial pressure. Subsequent MR imaging
studies were interpreted as intracerebral relapse of lymphoma.
The patient became somnolent, developed seizures and was admit-
ted to the ICU. A diagnostic work-up was initiated including blood
and CSF cultures, PCR-testing for pathogens in blood and CSF,
a bone marrow aspirate and brain biopsy. Still unaware of the re-
sults, the patient was treated with broad-spectrum antibacterial
drugs, acyclovir, ambisome, rituximab, dexamethasone and pyri-
methamine/sulfadiazine. His condition improved rapidly; cerebral
toxoplasmosis was proven by evidence of a positive PCR in CSFand detection of the pathogen in brain tissue. Another MRI two
weeks later showed the characteristic findings of cerebral toxoplas-
mosis with numerous ring-like contrast-enhancing lesions in both
hemispheres. One year later, the patient still has residual MRI find-
ings, but without neurological abnormalities. He is kept on toxo-
plasmosis maintenance therapy. Conclusion: In hematopoietic
stem cell transplant recipients, a diagnosis of cerebral toxoplasmosis
should be considered in every patient with sudden onset of acute,
neurological symptoms regardless of the presence of characteristic
findings on initial imaging studies.
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LONG TERM FOLLOW-UP IN THREE PEDIATRIC PATIENTS WITH
FARBER DISEASE, TYPE 2/3, FOLLOWING ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION FROM RELATED AND UNRELATED
DONORS
Ehlert, K.1, Frosch, M.2, Roth, J.2, Juergens, H.1, Vormoor, J.3. 1Uni-
versity Children’s Hospital, Muenster, Germany; 2University Children’s
Hospital, Muenster, Germany; 3Newcastle University, Newcastle upon
Tyne, United Kingdom.
Introduction: Farber Disease (FD) is an autosomal-recessively
inherited, lysosomal storage disorder caused by acid ceramidase de-
ficiency. FD, type 2/3, patients lack central nervous system involve-
ment, their clinical phenotype is dominated by the triad of a hoarse
voice, subcutaneous nodules and inflammatory granuloma around
the joints, resulting in severe, progressive contractures, deviation
of joints and finally considerable impairment of activities of daily
living or even complete immobility. Respiratory tract involvement
leads to death in the third or fourth decade of life. Allogeneic hema-
topoietic stem cell transplantation (HSCT) has been described as
a curative option for these patients. Here, we present the long
term follow-up data of three children after allogeneic HSCT with
encouraging results. Patients and Methods: The three children
were transplanted between May 2001 and February 2004 at the
age of 2, 3 and 4 years, respectively. The patients (female 2, male
1) received an allogeneicHSCT (MRD2,MUD1; stem cell source:
BM 2, PBSC 1) after busulfan-based myeloablative conditioning
regimens. GvHD prophylaxis consisted of CsA and short course
MTXwith (MUD) or without (MRD) rabbit-ATG. Transplant-re-
lated toxicities included acute GvHD, grade II (3), CMV-reactiva-
tion (1), bacterial infections (1) and CsA-associated neurotoxicity
(2). No chronic GvHD has been observed. Donor cell chimerism
is complete in one patient and partial in two patients. The follow-
up period is in a range between three and six years. Following the
first year post-transplant, all children were seen at least twice yearly
by the outpatient pediatric BMT unit and once yearly by pediatric
rheumatology. Pre-transplant all children had severe joint involve-
ment with pain and considerable restriction of motility; post-trans-
plant a rapid improvement and finally resolution of all nodules and
granulomas could be observed without evidence of residual im-
paired function. The children’s mental and motor development is
normal. Routine laboratory and organ function tests, endocrinolog-
ical and neurological studies have yielded normal results. The more
severely affected child with CsA-associated neurotoxicity (stroke
like event with seizures) has recovered completely. Summary: Fol-
low-up evaluation in three children three to six years after allogeneic
HSCT for Farber Disease, type 2/3, has revealed encouraging long-
term results without evidence of relapse, chronic GvHD or late ef-
fects.
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BUSULFAN AND SINGLE-DOSE MELPHALAN AS PREPARATIVE THERAPY
FOR INFANTS AND YOUNG CHILDREN UNDERGOING STEM CELL TRANS-
PLANTATION FOR LEUKEMIA: A SINGLE CENTER EXPERIENCE
Graham, M.L.1, Andreansky, M.1, Katsanis, E.1, Wood, T.S.2,
Hutter, J.J.1. 1University of Arizona Medical Center, Tucson, AZ;
2Phoenix Children’s Hospital, Phoenix, AZ.
Between January, 1996 andOctober, 2006, we treated 29 patients
under the age of 4 with ALL (n 5 15), AML (n 5 11), JMML (n 5
2), and CML (n 5 1) with a preparative regimen of Busulfan, 37.5
mg/m2 p.o. q 6 hours for 16 doses and Melphalan 140 to 180 mg/
